Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) President Dawn Christine Maroney sold 27,243 shares of Alignment Healthcare stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $15.43, for a total value of $420,359.49. Following the transaction, the president now directly owns 2,276,732 shares in the company, valued at approximately $35,129,974.76. This trade represents a 1.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Dawn Christine Maroney also recently made the following trade(s):
- On Thursday, March 6th, Dawn Christine Maroney sold 278,917 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.53, for a total transaction of $4,331,581.01.
- On Tuesday, February 18th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $13.72, for a total transaction of $411,600.00.
- On Wednesday, January 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $13.61, for a total transaction of $408,300.00.
Alignment Healthcare Price Performance
NASDAQ ALHC opened at $15.79 on Friday. Alignment Healthcare, Inc. has a 1 year low of $4.46 and a 1 year high of $16.25. The company has a fifty day simple moving average of $14.38 and a 200 day simple moving average of $12.41. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a market cap of $3.03 billion, a P/E ratio of -20.51 and a beta of 1.49.
Institutional Investors Weigh In On Alignment Healthcare
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Piper Sandler increased their price objective on Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Barclays lifted their price target on Alignment Healthcare from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Friday, February 28th. Stephens restated an “overweight” rating and issued a $17.00 price objective on shares of Alignment Healthcare in a report on Monday, February 24th. JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, March 6th. Finally, Stifel Nicolaus increased their price target on shares of Alignment Healthcare from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.83.
Read Our Latest Analysis on ALHC
About Alignment Healthcare
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Featured Stories
- Five stocks we like better than Alignment Healthcare
- What Are Dividends? Buy the Best Dividend Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Using the MarketBeat Dividend Yield Calculator
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.